Description
In the pathogenesis of Alzheimer’s Disease, GFAP serves as a critical indicator of astrocyte activation and reactive proliferation, appearing early in the disease continuum. Our GFAP Detection Kit, optimized for the Inspirer DX Analyzer, provides femtogram-level sensitivity, allowing clinicians to identify pathological changes 10–20 years before clinical symptoms manifest.
Key Features:
- Ultra-Sensitive Digital Detection: Utilizes single-molecule immunoassay technology to achieve a detection limit of 2.5 fg/mL, enabling the detection of plasma GFAP elevations that correlate strongly with Aβ plaque severity and neurofibrillary tangles.
- Proven Diagnostic Accuracy: Clinical evidence highlights significant GFAP upregulation in the cerebral cortex and hippocampus of AD patients; combining GFAP with Aβ42 and Tau biomarkers offers robust support for accurate AD diagnosis.
- Intelligent Digital Immunochip Workflow: Employs high-density microfluidic biochips and AI-based pattern recognition to capture and count individual fluorescent signals, ensuring unmatched data integrity.
- Non-Invasive Efficiency: Delivers high-precision results in just 20–30 minutes with a minimal 25 μL plasma volume, providing a practical alternative to invasive CSF collection or expensive PET imaging.
- Versatile Clinical Utility: An essential tool for auxiliary AD diagnosis, patient stratification, therapeutic efficacy monitoring in drug R&D, and neurological research.
Technical Specifications:
- Product Name: Human Glial Fibrillary Acidic Protein (GFAP) detection kit (Digital Immunoassay Chip Method).
- Packaging: 48 tests/box or 96 tests/box.
- Sample Compatibility: Human Plasma.
- System Integration: Fully optimized for the Inspirer DX Analyzer.
